INT 767
Alternative Names: Dual FXR/TGR5 agonists - Intercept Pharmaceuticals; FXR & TGR5 BA-derived backups - Intercept Pharmaceuticals; INT-767Latest Information Update: 13 Aug 2024
At a glance
- Originator Intercept Pharmaceuticals
- Class Anti-inflammatories; Antifibrotics; Bile acids and salts; Cholanes; Hepatoprotectants; Small molecules; Sulfates
- Mechanism of Action Farnesoid X-activated receptor agonists; G protein-coupled receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Diabetic nephropathies; Hepatic fibrosis; Metabolic disorders; Non-alcoholic steatohepatitis
Most Recent Events
- 05 Jun 2024 Interim pharmacodynamics data from a preclinical development in Metabolic disorders presented at the European Association for the Study of the Liver Congress 2024 (EASL Congress 2024)
- 08 Nov 2023 Intercept Pharmaceuticals has been acquired by Alfasigma
- 12 Nov 2021 Pharmacodynamics data from preclinical studies in Hepatic fibrosis presented at the 72nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2021)